Cargando…

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

Triple negative breast cancer accounts for 15–20% of all breast cancer cases, but despite its lower incidence, contributes to a disproportionately higher rate of mortality. As there are currently no Food and Drug Administration-approved targeted agents for triple negative breast cancer, we embarked...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solzak, Jeffrey P., Atale, Rutuja V., Hancock, Bradley A., Sinn, Anthony L., Pollok, Karen E., Jones, David R., Radovich, Milan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460220/ https://www.ncbi.nlm.nih.gov/pubmed/28649657 http://dx.doi.org/10.1038/s41523-017-0016-8

Ejemplares similares

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
por: Hancock, Bradley A., et al.
Publicado: (2019)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Chen, Yu-Hsiang, et al.
Publicado: (2017)

A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas
por: Radovich, Milan, et al.
Publicado: (2016)

Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors
por: Garcia, Ana Rita, et al.
Publicado: (2023)

Wnt signaling in triple-negative breast cancer
por: Pohl, SÖ-G, et al.
Publicado: (2017)

A phase II study of buparlisib in relapsed or refractory thymomas
por: Abu Zaid, Mohammad I., et al.
Publicado: (2022)

Wnt signaling in triple negative breast cancer is associated with metastasis
por: Dey, Nandini, et al.
Publicado: (2013)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Prvanović, Mirjana, et al.
Publicado: (2021)

Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice
por: Zhang, Tian, et al.
Publicado: (2017)

Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy
por: Mustafi, Sushmita, et al.
Publicado: (2021)

Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank
por: Pardo, Ivanesa, et al.
Publicado: (2014)

Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K–AKT Pathway
por: Zhang, Daoyu, et al.
Publicado: (2020)

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2019)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Triple-negative breast cancer: understanding Wnt signaling in drug resistance
por: Merikhian, Parnaz, et al.
Publicado: (2021)

Synergistic interactions with PI3K inhibition that induce apoptosis
por: Zwang, Yaara, et al.
Publicado: (2017)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
por: Xu, Yonggang, et al.
Publicado: (2021)

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
por: Amante, Romain J., et al.
Publicado: (2023)

Dual inhibition of Wnt and Yes‐associated protein signaling retards the growth of triple‐negative breast cancer in both mesenchymal and epithelial states
por: Sulaiman, Andrew, et al.
Publicado: (2018)

N-Cadherin Negatively Regulates Osteoblast Proliferation and Survival by Antagonizing Wnt, ERK and PI3K/Akt Signalling
por: Haÿ, Eric, et al.
Publicado: (2009)

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma
por: Daenthanasanmak, Anusara, et al.
Publicado: (2022)

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
por: Subtil, Florentine S. B., et al.
Publicado: (2022)

GPRC5A Is a Negative Regulator of the Pro-Survival PI3K/Akt Signaling Pathway in Triple-Negative Breast Cancer
por: Yang, Lu, et al.
Publicado: (2021)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer
por: Johnson, Jeremy, et al.
Publicado: (2020)

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
por: Guo, Zhanfang, et al.
Publicado: (2020)

MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade
por: Wang, Wei, et al.
Publicado: (2022)

PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer
por: Guo, Fengzhu, et al.
Publicado: (2023)

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers
por: De, Pradip, et al.
Publicado: (2016)

The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells
por: Cai, Jiajing, et al.
Publicado: (2020)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly
por: Giovannelli, Pia, et al.
Publicado: (2019)

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
por: Chan, Jack J., et al.
Publicado: (2019)

Wnt modulates MCL1 to control cell survival in triple negative breast cancer
por: Yang, Lixin, et al.
Publicado: (2014)

Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells
por: Maubant, Sylvie, et al.
Publicado: (2015)

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells()
por: Wu, Y. Linda, et al.
Publicado: (2017)

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2020)

Sinomenine sensitizes human gastric cancer cells to cisplatin through negative regulation of PI3K/AKT/Wnt signaling pathway
por: Liu, Ying, et al.
Publicado: (2019)

Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
por: Guo, Shang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n6l2uenod8vjn35sq1kd37p1lv